sur ABIVAX (EPA:ABVX)
Abivax Joins CAC Mid 60 and SBF 120 Indices
On September 12, 2025, Abivax, a clinical-stage biotechnology company, announced its inclusion in the CAC Mid 60 and SBF 120 indices following the annual review by Euronext Paris. This change will take effect on September 19, 2025, after market close. The indices represent mid-sized and major securities on the Euronext Paris exchange, respectively.
The inclusion is expected to enhance Abivax's visibility, making its shares more accessible to institutional investors and funds linking them to indices. Marc de Garidel, CEO of Abivax, expressed that this addition is a recognition of market confidence in the company's strategic visions and their execution. It aligns with Abivax's commitment to providing innovative therapies for chronic inflammatory diseases and generating long-term shareholder value.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de ABIVAX